相关实验视频
Updated: Feb 21, 2026

08:56
Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
5.7K
活生物治疗药物的临床应用:当前趋势和未来前景
1Center for Engineered Therapeutics, Brigham and Women's Hospital, Cambridge, MA, United States.
Progress in molecular biology and translational science
|February 19, 2026
概括
活生物疗法 (LBPs) 通过使用活生物体为疾病提供了新的治疗方法. 尽管面临挑战,但LBP在传染病,瘤学和代谢健康方面表现有前途,将医学转向生态模型.
科学领域:
- 微生物组科学 微生物组科学
- 翻译医学是一种翻译医学.
- 活生物疗法 (LBPs) 是一种生物疗法.
背景情况:
- 美国食品和药物管理局 (FDA) 将活生物疗法 (LBPs) 定义为含有用于治疗疾病的活生物体的生物产品,不包括疫苗.
- 微生物组科学和抗生素限制的进步推动了各种医学领域的LBP开发.
- 便微生物种移植已经验证了对复发性C. difficile感染的生态恢复,导致批准的LBPs.
研究的目的:
- 审查现有生物疗法 (LBPs) 在各种医疗学科中的当前应用和未来潜力.
- 突出在构建微生物联盟和治疗干预的菌株级策略方面取得的进展.
- 确定挑战,并提出解决方案,从研究转化LBP到临床实践.
主要方法:
- 关于活生物疗法 (LBPs) 和微生物组研究的科学文献的综述.
- 对LBP在传染病,瘤学,代谢障碍,过敏和口腔健康方面的应用进行分析.
- 讨论包括患者反应变化,制造,安全,成本和监管协调在内的挑战.
主要成果:
- 在传染病方面,LBP已经取得了显著的成功,以复发性C. difficile感染的治疗为例.
- 微生物联盟和工程细菌正在开发,以增强癌症免疫疗法和对抗多药耐药生物.
- 早期研究表明LBP在代谢疾病,过敏和口腔健康方面的潜力,目前正在研究精密配方.
结论:
- 活生物疗法 (LBPs) 代表了向生态治疗模式的范式转变,提供了新的治疗策略.
- 克服制造,安全,成本和监管协调方面的障碍对于更广泛的LBP采用至关重要.
- 未来的方向包括精密微生物联盟和可编程的"活药",以扩大治疗指示和全球健康影响.
相关概念视频
Microorganisms in Medicine and Therapeutics
1.2K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.2K
Issues And Trends In Healthcare Delivery System
6.3K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.3K
Drug Products: Biologics, Biosimilars and Interchangeables
293
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
293
Hybridoma Technology
17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K
Clinical Applications of Epidermal Stem Cells
3.3K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
234
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
234

